Published October 23, 2023
| Version v1
Journal article
Open
MODERN METHODS OF TREATING GOUT
Creators
- 1. Termez branch of the Tashkent Medical Academy Department of Internal Medicine, Military Field Therapy, Hematology and Family Medicine Therapy
- 2. Termez branch of the Tashkent Medical Academy department of internal medicine propaedeutics, rehabilitation, folk medicine, endocrinology
Description
Gout is a systemic tophi disease from the group of microcrystalline arthritis, which is characterized by the deposition of monosodium urate crystals in various tissues and the inflammation that develops in connection with this in individuals with hyperuricemia caused by environmental and/or genetic factors. Over the past decades, it has been considered one of the most studied and treatable rheumatic diseases, however, the frequency of errors made when prescribing therapy for patients with gout remains extremely high.
Files
258-263 Berdieva Rano Sultonovna.pdf
Files
(901.2 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:bbc2ca4e99cb635063a9ff8d9838c5f4
|
901.2 kB | Preview Download |
Additional details
References
- 1. Елисеев М. С., Барскова В. Г. Влияние росиглитазона на показатели углеводного и уратного обмена у больных подагрой: Тез. докл. IV Всероссийского диабетологического конгресса. — М., 2008. — С. 102.
- 2. Ильина А. Е., Барскова В. Г. Применение урисана при подагре // Современная ревматология. — 2008. — № 1. — С. 81–83.
- 3. Кудаева Ф. М., Елисеев М. С., Барскова В. Г. и др. Сравнение скорости наступления анальгетического и противовоспалительного эффектов различных форм нимесулида и диклофенака натрия при подагрическом артрите // Тер. архив. — 2007. — № 5. — С. 35–40.
- 4. Насонова В. А., Барскова В. Г. Ранние диагностика и лечение подагры — научно обоснованное требование улучшения трудового и жизненного прогноза больных // Научно-практическая ревматология. — 2004. — № 1. — С. 5–7.
- 5. Allovay J. A., Moriarty M. J., Hoogland Y. T. et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis // J. Rheumatol., 1993; 20: 111–113.
- 6. De La Serna G., Cadarso C. Fenofibrate decreases plasma fibrinogen, improves lipid profile and reduces uricaemia // Clin. Pharmacol. Ther., 1999; 66: 166–172.
- 7. Dessein P., Shipton E., Stanwix A. et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study // Ann. Rheum. Dis., 2000; 59: 539–543.
- 8. Eliseev M. S., Barskova V. G., Volkov A. V. et al. The efficacy and safety of metformin treatment in gouty patients with insulin resistence syndrome (pilot case control 6-months study) // Ann. Rheum. Dis., 2005; 64 (suppl. 3): 500.
- 9. Emmerson B. T. The management of gout // N. Engl. J. Med., 1996; 334: 445–451.
- 10. Feher M. D., Hepburn A. L., Hogarth M. B. et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout // Rheumatology, 2003; 42: 321–325.